Join Our Community

Take advantage of our member benefits when you sign up | log-in
Web Search powered by YAHOO!

Published: August 28, 2008
Business Briefs
NATION Genentech stands still on blindness treatments WASHINGTON — What does a company do when there's anecdotal evidence that two of its drugs are equally effective in treating a leading cause of blindness in the elderly, one costing patients $60 per treatment and the other $2,000?

In the case of Genentech Inc. , nothing.

The company declined to seek federal approval for the cheaper drug, Avastin , to...

You have selected to view an article that is older than 60 days. Get access to all our historical content by purchasing a pass to The Oklahoman. Select the option that works best for you.

Archive Subscription types & rates
One-year subscription $248.00 One-month subscription $33.00
  Six-month subscription $140.00   One-day pass $8.95
  Three-month subscription $78.00   This article $1.49

               



CONTACT US



PHOTOS
Upload your photos to NewsOK and share them with the world.


VIDEO
Upload your videos to NewsOK and share them with the world.


STORIES
Share your story idea with The Oklahoman.